GLP-1 Lean-Mass Change: Protein & Strength

Weight loss with semaglutide or tirzepatide includes fat mass and lean mass. That does not mean a reported percentage of lean loss is a percentage of muscle destroyed. DXA, the method used in major substudies, groups skeletal muscle with water, organs, connective tissue, and other non-fat soft tissue. The useful response is to monitor nutrition, strength, and function while the prescribing team monitors treatment.

Medical disclaimer. This article is for general educational purposes only and is not medical advice. It is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider before starting the ketogenic diet or making changes to your diet, exercise, or medication — especially if you are pregnant or breastfeeding, take medication, or have a medical condition such as diabetes, or kidney, liver, or heart disease. See our editorial & medical-review policy.

Semaglutide is a GLP-1 receptor agonist. Tirzepatide acts at GIP and GLP-1 receptors. The studies below assessed specific medicines and populations; their numbers should not be turned into a guarantee for every medicine or patient.

What did the semaglutide substudy find?

The STEP 1 exploratory DXA substudy included 140 adults with overweight or obesity: 95 assigned to semaglutide 2.4 mg and 45 to placebo. At week 68, the semaglutide group had mean changes of:

• 15.0% in body weight;
• 19.3% in total fat mass;
• 27.4% in visceral fat mass; and
• 9.7% in total lean body mass.¹

The proportion of body weight classed as lean increased by about 3 percentage points because fat mass declined faster. This was an exploratory subset, not the full STEP 1 trial, and it did not directly measure skeletal-muscle tissue or muscle quality.

What did the tirzepatide substudy find?

The SURMOUNT-1 DXA substudy enrolled 160 participants from the larger trial: 124 assigned to pooled tirzepatide doses and 36 to placebo. At week 72, mean changes with tirzepatide were 21.3% in body weight, 33.9% in fat mass, and 10.9% in lean mass.² The investigators estimated that about 74% of weight lost was fat mass and 26% was lean mass. The corresponding ratio in the placebo group was about 75% to 25%.

These subgroup results do not justify the claim that everyone loses a fixed 15-40% of their weight as muscle. The trials used different medicines, designs, subsets, and analyses. They also measured lean tissue by DXA, not skeletal muscle alone.

How should protein targets be interpreted?

Three benchmarks answer different questions:

Benchmark	Number	What it means
Adult DRI RDA	0.8 g/kg/day	Intake designed to meet the needs of about 97-98% of healthy adults3
2025-2030 Dietary Guidelines	1.2-1.6 g/kg/day	A general daily protein goal in the current U.S. guidance4
GLP-1 nutrition advisory	Several proposed approaches	A clinical discussion with no consensus weight basis for people with obesity5

The 0.8 g/kg RDA is not simply the amount that prevents overt deficiency. The 1.2-1.6 g/kg guidance is a broad public-health goal, not an automatic prescription based on actual body weight for every person using a GLP-1 medicine.

The four-society GLP-1 advisory discusses protein based on body weight, adjusted body weight, ideal body weight, or fat-free mass and says consensus is lacking about which basis to use in obesity.⁵ Kidney disease, cirrhosis, pregnancy, frailty, athletic training, and low energy intake require additional context. For example, KDIGO advises about 0.8 g/kg/day in adults with CKD stages G3-G5 and avoiding intake above 1.3 g/kg/day when progression risk is present.⁶ AASLD guidance for stable cirrhosis instead recommends 1.2-1.5 g/kg of ideal body weight per day and warns against routine protein restriction.⁷

The keto calculator is an input-only macro arithmetic worksheet. It calculates results from values you enter; it does not choose a personalized protein or macro target.

Why resistance training belongs in the plan

The joint advisory concludes that protein alone is likely insufficient to preserve muscle without structured resistance training.⁵ Direct trials have not established one universally effective GLP-1 routine. A plan needs to reflect current strength, mobility, medical conditions, calorie intake, and training experience.

Useful categories include a knee-dominant movement, a hip-dominant movement, a push, a pull, and loaded carrying or grip work. Machines, free weights, bands, and body-weight exercises can all create resistance. A qualified professional can scale them for joint pain, balance limits, cardiovascular disease, or long periods without training.

Track function as well as scale weight. Examples include the load or repetitions used in a consistent exercise, chair-rise ability, walking pace, grip tasks, and whether routine activities are getting easier or harder. A short-term weak session is not proof of tissue loss. A sustained decline, new falls, or difficulty with daily tasks warrants clinical review.

What about keto and creatine?

No randomized trial has shown that combining a ketogenic diet with a GLP-1 medicine preserves more muscle than an otherwise adequate diet. Low-carbohydrate eating may still be a personal preference, but adequate energy, micronutrients, tolerated fiber, and medication safety remain relevant. Start with what to eat on a GLP-1 and review keto while taking a GLP-1 with the prescribing team.

Creatine monohydrate has general resistance-training evidence, but direct evidence for creatine during GLP-1 treatment is absent and keto-specific evidence is sparse. It can also raise serum creatinine without a demonstrated fall in measured kidney filtration, which can complicate creatinine-based eGFR interpretation. Our creatine on keto guide explains those limits.

A practical review list

Bring these questions to a prescribing or nutrition visit:

• Is the rate of weight loss and current food intake clinically appropriate?
• Which body-weight basis should be used for a protein target?
• Are symptoms preventing adequate food or fluid intake?
• Are strength and daily function stable?
• Do kidney, liver, pregnancy, frailty, or medication factors change the plan?
• Would a dietitian or appropriately qualified exercise professional help?

Do not change or stop a medicine because a home scale reports a lean-mass estimate. Consumer bioimpedance readings move with hydration and are not interchangeable with DXA.

Frequently Asked Questions

Does GLP-1 treatment always cause muscle loss?

Weight loss commonly includes some lean mass, but DXA lean mass is broader than skeletal muscle. The amount varies, and major substudies do not establish a universal percentage of muscle loss for every patient.

What did STEP 1 show about lean mass?

In a 140-person exploratory DXA substudy, the semaglutide group lost 15.0% body weight, 19.3% fat mass, and 9.7% lean mass at week 68. The proportion of body weight classed as lean increased because fat fell faster.

Is 0.8 g/kg only a deficiency minimum?

No. The National Academies set the adult RDA of 0.8 g/kg/day to cover about 97-98% of healthy adults. Other goals may be used in different contexts, but the RDA should be described accurately.

Should everyone on a GLP-1 use 1.2-1.6 g/kg of actual body weight?

No. Current Dietary Guidelines use that range as a general goal, while the GLP-1 nutrition advisory notes no consensus on the right weight basis in obesity. Clinical conditions can materially change the target.

Can protein replace resistance training?

Current professional guidance says protein by itself is likely insufficient for muscle preservation. Training should be scaled to health, mobility, and experience.

Works cited

1. Wilding JPH, Batterham RL, Calanna S, et al. Impact of Semaglutide on Body Composition in Adults With Overweight or Obesity: Exploratory Analysis of the STEP 1 Study. Journal of the Endocrine Society. 2021. https://pmc.ncbi.nlm.nih.gov/articles/PMC8089287/
2. Look M, Dunn JP, Kushner RF, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes, Obesity and Metabolism. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC11965027/
3. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids, National Academies, 2005 https://www.nationalacademies.org/publications/10490
4. Dietary Guidelines for Americans, 2025-2030, U.S. Departments of Health and Human Services and Agriculture, January 2026 https://cdn.realfood.gov/DGA.pdf
5. Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional Priorities to Support GLP-1 Therapy for Obesity: A Joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity. 2025. https://doi.org/10.1002/oby.24336

Article history

1. August 23, 2026Rebuilt lean-mass interpretation, trial results, protein benchmarks, and resistance guidance from primary studies
2. August 21, 2026First published